8-K: Exicure Acquires GPCR Therapeutics USA, Enters Licensing Agreement

Exicure Inc. has acquired GPCR Therapeutics USA and entered into a licensing agreement to further develop and commercialize GPCR technologies.

Summary

• Exicure Inc. acquired GPCR Therapeutics USA from GPCR Therapeutics Inc. for approximately $1.62 million, purchasing six million shares at about $0.27 per share.
• The acquisition closed concurrently with the execution of the Share Purchase Agreement.
• Exicure also entered into a License and Collaboration Agreement with GPCR to develop and commercialize GPCR technologies.
• Exicure will make milestone payments to GPCR based on clinical trial achievements, marketing authorizations, and net sales.
• A recurring royalty payment of at least 10% of net sales is also required under the agreement.
• GPCR USA is developing treatments including Opdivo, an autoimmune disease treatment with $10 billion in annual revenue, and Yervoy, a cancer treatment.
• GPCR USA is currently conducting a Phase 2 clinical trial for blood cancer patients using a combination of GPC-100 and propranolol.
• The trial aims to treat 20 patients by April, with results expected in September.
• GPCR USA presented data in December showing a tenfold increase in anti-cancer efficacy when inhibiting both CXCR4 and ADRB2.
• The ongoing clinical trials have met all primary evaluation indicators and are at the stage of deciding whether to proceed to Phase 3.

Sentiment

Score: 7

Explanation: The acquisition and licensing agreement are positive developments, but the company still faces risks and uncertainties. The potential for growth is significant, but the success of the clinical trials is not guaranteed.

Positives

• The acquisition provides Exicure with access to GPCR USA's pipeline of promising treatments.
• The licensing agreement allows Exicure to leverage GPCR's technologies for further development and commercialization.
• GPCR USA's ongoing clinical trials have met all primary evaluation indicators.
• The potential for expansion into cell and gene therapies is a positive development for Exicure.
• The research into obesity treatments could provide additional opportunities for growth.

Negatives

• Exicure is required to make milestone payments and pay a 10% royalty on net sales to GPCR.
• The company is still exploring strategic alternatives after restructuring and suspending clinical activities.
• There is no guarantee that the clinical trials will be successful or that the treatments will be approved.

Risks

• There is a risk that Exicure may not be able to comply with Nasdaq listing requirements.
• The success of the clinical trials and the commercialization of the technologies are not guaranteed.
• The company faces competition from other biotechnology companies.
• The company is dependent on the success of GPCR USA's research and development.

Future Outlook

Exicure is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. The company will continue to develop and commercialize GPCR technologies and is considering collaborations with companies possessing antibody manufacturing technologies.

Management Comments

• Dr. Caderelli stated that positive results from the GPC-100 trial could have a beneficial impact on attracting additional investment and enhancing corporate value.
• Dr. Caderelli suggested that in the future, it will be essential to prioritize discussions with various partners based on the likelihood of success and high return on investment.
• Dr. Caderelli mentioned that they are also researching interesting hypotheses, such as obesity treatments.

Industry Context

This acquisition and licensing agreement indicate a strategic shift for Exicure, moving from its historical focus on nucleic acid therapies to exploring new opportunities in GPCR technologies. This is a competitive area with many companies developing similar treatments, but the potential for high returns is significant.

Comparison to Industry Standards

• The acquisition of GPCR USA is a strategic move for Exicure, similar to other biotech companies acquiring promising assets to expand their pipelines.
• The 10% royalty rate is within the typical range for licensing agreements in the biotechnology industry.
• The development of treatments like Opdivo and Yervoy, which generate billions in revenue, highlights the potential for high returns in this sector.
• The Phase 2 clinical trial for GPC-100 is a common step in drug development, with the next step being a Phase 3 trial if results are positive.
• The focus on combining CXCR4 and ADRB2 inhibition is a novel approach, but it is still in early stages of development.

Stakeholder Impact

• Shareholders may benefit from the potential growth and value creation from the acquisition and licensing agreement.
• Employees may have new opportunities as the company expands its operations.
• Customers may benefit from the development of new treatments.
• Suppliers may have new business opportunities with Exicure.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• Exicure will continue to develop and commercialize GPCR technologies.
• GPCR USA will complete the Phase 2 clinical trial for GPC-100.
• Exicure will consider collaborations with companies possessing antibody manufacturing technologies.
• Exicure will prioritize discussions with various partners based on the likelihood of success and high return on investment.

Key Dates

Keywords

acquisition, biotechnology, licensing agreement, clinical trials, GPCR, cancer treatment, autoimmune disease, milestone payments, royalty, GPC-100